Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

d increased personal and personal related costs for our technical operations. For the year ended December 31, 2008, increased expenses resulted from investments in our development programs, increased medical education activities and increased marketing activities.

Our effective income tax rate was a benefit of 76.3 percent and an expense of 18.0 percent for the quarters ended December 31, 2008 and 2007, respectively and an expense of 22.4 percent and 29.7 percent for the year ended December 31, 2008 and 2007, respectively. Our income tax expense includes federal, state and foreign income taxes at statutory rates and the effects of various permanent differences. The decrease in the 2008 rate as compared to 2007 is primarily due to the impact of the orphan drug credit for maribavir and the decreased level of income before taxes.

Working Capital Highlights

As of December 31, 2008, ViroPharma's working capital was approximately $305.4 million, which represents a $289.0 million decrease from December 31, 2007, caused by a $366.4 million decrease in the fourth quarter of 2008 mainly related to the acquisition of Lev ($380.2 million), offset slightly by operating cash flows. Cash flow from operating activities for the three months and year ended December 31, 2008 was $0.6 million and $91.4 million, respectively.

Business Development Highlights

In October 2008, we completed our acquisition of Lev. Lev was a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The terms of the merger agreement provided for the conversion of each share of Lev common stock into upfront consideration in the aggregate amount of $442.9 million, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock, and contingent consideration (CVRs) of up
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Over the ... primarily due to rising R&D budgets and increased acceptance ... fast growing pharmaceutical and biotechnology industries are also catalyzing ... laboratory filtration market is expected to grow at a ... is estimated to be worth $2,532.6 million by 2019. ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... Expands Decision Resources, Inc.,s Portfolio to Include Global ... Physician and Consumer Digital Market Research, ... Inc., one of the world,s leading research and advisory ... it,acquired Manhattan Research, a leading provider of access to ...
... AVIV, Israel, June 17 BSP Ltd.,( http://www.bsp.co.il/pressall.asp ... for non-invasive diagnosis and monitoring of Ischemic Heart,Disease, ... a private,funding round, that included existing shareholders in ... developed the HyperQ(TM), a cutting-edge technology that offers,highly ...
... and fast PCR amplification ... in a fully portable ... a leading,developer of state-of-the-art PCR devices and Cell-based assay systems,today ... San,Diego Convention Center that it has successfully completed development of,Palm ...
Cached Biology Technology:Decision Resources, Inc. Acquires Manhattan Research 2Decision Resources, Inc. Acquires Manhattan Research 3BSP Raises $2.6 Million Dollars From Private Investors 2Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device 2
(Date:9/30/2014)... . FRANKFURT. Truffles, ... the world. Because they grow underground, people use trained dogs ... truffles is not only of interest to gourmets. A group ... Goethe University Frankfurt have discovered that the smell of white ... inside truffle fruiting bodies. , White truffles from the Piedmont ...
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... available in German . ... response to risky situations such as exposure to predators. ... found in a long-term study on different populations of ... rate and ambient temperature. High metabolic rates and low ... these scenarios birds were more likely to approach potential ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2
... As the 2010 United Nations International Year of ... (MBG) and the Royal Botanic Gardens, Kew (RBG Kew) ... international resource is a working list of all land ... diversity and effective conservation of plants. The completion of ...
... In a recent issue of HortTechnology , Purdue ... on a study of the effects of a technique called ... are commonly applied as sprays or media drenches, bulb crops ... The experiments were designed to determine if dipping Easter lily ...
... Dec. 29, 2010 Patients with diabetes, kidney disease and ... have a higher risk of cardiovascular disease or death, researchers ... results suggest that testing such patients, responsiveness to the drug ... their risk, said Dr. Robert Toto, professor of internal medicine ...
Cached Biology News:Kew Gardens and Missouri Botanical Garden announce the completion of the Plant List 2Kew Gardens and Missouri Botanical Garden announce the completion of the Plant List 3Bulb dipping controls Easter lily growth 2Poor response to anti-anemia drug predicts higher risk of heart disease or death 2Poor response to anti-anemia drug predicts higher risk of heart disease or death 3
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
... designed for sequencing inserts cloned into M13/pUC-based ... T3 RNA polymerase promoters, or lambda gt10 ... a concentration of 0.1 µg/µl in water. ... sequencing reactions using SequiTherm™ EXCEL™ II DNA ...
... Expression is a powerful application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
... with AutoGen AutoGenesys, BioRobotics BioPick, BioGrid, TAS ... picking systems This CLS number is a ... Cornings product number. If showing no availability ... number (D9314) or contact customer service for ...
Biology Products: